Medpace (NASDAQ:MEDP) Stock Price Up 0.6%

Medpace Holdings, Inc. (NASDAQ:MEDP)’s share price was up 0.6% during trading on Thursday . The stock traded as high as $402.11 and last traded at $400.11. Approximately 52,823 shares were traded during trading, a decline of 79% from the average daily volume of 248,554 shares. The stock had previously closed at $397.86.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MEDP shares. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and raised their price target for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Finally, Robert W. Baird raised their price target on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Medpace presently has an average rating of “Moderate Buy” and a consensus target price of $443.00.

Medpace Trading Down 1.0 %

The company’s fifty day simple moving average is $398.32 and its 200 day simple moving average is $328.94. The stock has a market capitalization of $12.20 billion, a P/E ratio of 40.79, a P/E/G ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same period last year, the firm earned $2.27 EPS. The business’s quarterly revenue was up 17.7% compared to the same quarter last year. Equities research analysts predict that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Insider Buying and Selling at Medpace

In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the completion of the transaction, the insider now directly owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, major shareholder Medpace Investors, Llc sold 50,000 shares of Medpace stock in a transaction on Friday, February 16th. The shares were sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the sale, the insider now directly owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the sale, the chief executive officer now directly owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The disclosure for this sale can be found here. Insiders sold a total of 204,442 shares of company stock valued at $82,702,867 in the last three months. Company insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

Several hedge funds have recently added to or reduced their stakes in MEDP. Wellington Management Group LLP lifted its stake in Medpace by 312.6% in the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after purchasing an additional 319,210 shares during the last quarter. TD Asset Management Inc lifted its stake in Medpace by 195.2% in the fourth quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock worth $143,162,000 after purchasing an additional 308,816 shares during the last quarter. Invesco Ltd. lifted its stake in Medpace by 67.6% in the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after purchasing an additional 246,775 shares during the last quarter. Findlay Park Partners LLP bought a new stake in Medpace in the first quarter worth $90,247,000. Finally, Norges Bank bought a new stake in Medpace in the fourth quarter worth $59,163,000. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.